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population would be ca 130,000,000 PLN in 2011 and will steadily increase to ca
202,000,000 PLN in 2015. In case of tenofovir reimbursement estimated decrease in
total expenditures will be ca 6,000,000 PLN in 2011 and ca 11,000,000 PLN in 2015.
CONCLUSIONS: The decision for tenofovir reimbursement will cause decrease in
public payer expenditures for patients with chronic hepatitis B.
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OBJECTIVES: Budget impact analysis of chronic hepatitis (HCV) pharmacotherapy
with pegylated interferon alfa-2a (PegIFN alfa-2a) and pegylated interferon alfa-2b
(PegIFN alfa-2b).METHODS: The study used a Budget Impact Analysis method with
the Rational Drug Use Indicator (RDUI), which allows to quantitatively describe the
economic effectiveness of a particular drug taking into account its useful applica-
tion potential. The modeling was based on the data collected in IDEAL clinical
study. The model considered two groups of HCV genotype 1 patients, equal in
number (1000 patients per group) and comparable in demographic, clinical, and
virological characteristics: group 1 – patients receiving PegIFN alfa-2a, group 2 –
PegIFN alfa-2b. Patients’ age and weight, as well as the drug dose were taken into
account. A sensitivity analysis was performed in modeling the number of patients
treated with PegIFN alfa-2a and PegIFN alfa-2b. RESULTS: It is estimated that under
the given model conditions the direct costs per patient in PegIFN alfa-2a treatment
of hepatitis C for 48 weeks amounted to 419,199.36 rubles, and PegIFN alfa-2b –
422,637.12. The direct costs difference in the 1: 1 ratio of patients treated with
PegIFN alfa-2a and PegIFN alfa-2b amounted to 1,718,880 rubles. As shown by the
RDUI calculation, inefficient budget expenditure in the case of using PegIFN alfa-2b
in 1,000 patients during the analyzed treatment period may reach 63,395,570 ru-
bles. The results sensitivity analysis according to RDUI revealed a dependence of
the budget losses on the share of patients receiving PegIFN alfa-2a and PegIFN
alpha-2b. CONCLUSIONS: When comparing the budget impact by PegIFN alfa-2a
and PegIFN alfa-2b HCV treatment strategies, the economic expediency of the
strategy of using PegIFN alfa-2a in Russian patients was identified.
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OBJECTIVES: This study aimed to assess the efficiency of the 13-valent pneumococcal
conjugate vaccine (PCV13) administered annually to 65-years-old cohort in Spain versus
the alternative of not vaccinating and treating patients only when infected. METHODS:
Infections avoided were calculated through a dynamic model based on Anderson
and May work. 70% of the 65-years-old cohort was assumed as vaccinated with one
PCV13 dose (318,000 subjects). Basecase estimated vaccine efficacy and serotype
coverage were as follows (75% and 70% respectively). Disease cost was calculated
based on CMBD database and published data. RESULTS: During the 5 years frame,
a total of 83,844 infections would be avoided. Net savings of €62 million would be
obtained. The distribution of the savings was not homogeneous, starting in the 3rd
and increasing until the 5th year. To demonstrate model robustness, analyses of
additional scenarios have been performed using extreme values of model param-
eters (vaccination programme coverage, vaccine efficacy, serotype coverage). Un-
der those scenarios, the net savings results were always achieved. CONCLUSIONS:
After three years, 65-year-cohort pneumococcal vaccination campaign appeared to
be a cost saving intervention among Spanish population under different scenarios.
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OBJECTIVES: Evaluation of comparative cost-effectiveness of treatment of CAP
complicated by sepsis with moxifloxacin compared to ceftriaxone  azithromycin
in adult patients. METHODS: literature search revealed prospective non-random-
ized comparative controlled clinical trial (n87) where treatment efficacy of CAP
complicated by sepsis was evaluated. MOX group received moxifloxacin (400 mg
i.v.) 3-4 days with further switch to 400 mg per os daily. CEAZ group received
combined therapy with ceftriaxone 2000 mg i.v. and azithromycin 5000 mg during
5 days. Efficacy criteria were length of antibacterial treatment, ICU and in-hospital
days. Cost-effectiveness analysis was performed. RESULTS: Patients of MOX group
spent 2.71.3 ICU days compared to 3.91.4 days (p0.05) in CEAZ group. Antimi-
crobial treatment took 7.00.4 days in MOX and 10.00.5 days in CEAZ group
(p0.05). There was not statistically significant deference in hospital days. Costs of
antibacterial treatment and ICU stay were 17,803 RUR (€447) per patient in MOX
group and 19,020 (€478) in CEAZ group. CONCLUSIONS: treatment of CAP compli-
cated by sepsis with moxifloxacin compared to combined therapy in adult patients
leads to ICU stay reduction by 1.2 days and cost saving by 1216 RUB (€31).
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OBJECTIVES: The objective was to compare two modeling approaches to estimate
the future burden of hepatitis C in selected countries. Due to varying efficacy de-
pending on host factors such as viral load at baseline, disease duration, pre-treat-
ment status, and disease severity more complex modeling is required. METHODS:
Two models were developed. Model A was based on a classic Markov model with
seven disease states modeling the impact of the new drugs based on response-
guided therapy and efficacy. Drug acquisition cost, treatment management and
annual health care cost were determined and the potential budget impact was
assessed. Several “what if” analyses were performed. Model B is a dynamic, indi-
vidual-based, stochastic model providing a powerful tool to perform sensitivity
analysis on uncertain and disputed parameters. All input variables (incidence,
prevalence, genotype distribution, cost, drug efficacy) were derived from a system-
atic literature and database review and analysis. RESULTS: In “what if” scenarios
with varying treatment rates the time and cost to potential elimination of hepatitis
C were modeled. Assuming all patients currently infected with hepatitis C would be
treated from 2012 onwards, with efficacies (SVR) ranging between 70% and 80%,
and assuming constant infection rates resulted in elimination of hepatitis C by the
year 2030 in model A. In model B, in which individual-based host factors were taken
into account, elimination was not achieved in the same time period. Different
“what if” scenarios for non-responders, variations in baseline host factors, poten-
tial relapses and development of resistance were modeled more reliable with the
individual-based model. CONCLUSIONS:Modeling “what if” scenarios on the basis
of expected drug efficacy utilizing a dynamic, individual-based stochastic model
results in a more comprehensive tool to estimate the distribution of expected
future burden of HCV.
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OBJECTIVES: The epidemiological transition for HIV-infection from a fatal condi-
tion to a chronic disease, has significant impact on decision-making process to
ensure therapy appropriateness and to monitor the rising costs of antiretroviral
(ARV) therapy. Starting from Lombardy Region’s MOLO Project (MOnoterapia LOpi-
navir), this analysis aims to develop a methodological model based on treatment
appropriateness, and to carry out an impact assessment of the simplification to
monotherapy with lopinavir/ritonavir for HIVpatients vs. standard therapy (NRTI
backbone plus a third agent). METHODS: From the cohort of 23,721 HIV patients,
according to eligibility criteria of 2010 Italian Guidelines, a static and dynamic (5ys)
decisional model was produced to study the evolution of the disease, correlating
clinical developments with total costs of population under assessment. The model
provides 2 possible scenarios: monotherapy control or failure leading to re-induc-
tion. Cost of medicines, DRGs, lab tests and all other costs were inputted. The
budget impact analysis was completed with an impact assessment comprehensive
of: cost-effectiveness analysis, organizational, ethics and equity impact of treat-
ment options. RESULTS: The analysis showed that the simplification to mono-
therapy with lopinavir/ritonavir could affect a significant sector of HIV patients,
bringing economic benefits from 10.7 to 21.6MM€, in the first year. Analyzing the
entire diagnostic clinical pathway, the analysis showed savings of 10.8 to 22.6MM€,
and of 47.6 to 144.8 MM€ from 2,011 to 2,016. Monotherapy with lopinavir/ritonavir
also ensures a better result vs. standard in terms of cost-effectiveness (14.007€ vs.
11.673€ in the most conservative hypothesis). Organizational impact doesn’t show
any differences between the two approaches, ethical impact is positive to the pa-
tients as regards long-term toxicity. CONCLUSIONS: The result of the analysis
suggests that national and regional decision makers have considerable space for
maneuver into a more appropriate position for resources management, without
changing the efficacy and safety results of patients.
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OBJECTIVES: The Veterans Health Administration (VHA) is the largest single pro-
vider of hepatitis C (HCV) care in the United States. The newly approved direct
acting antivirals (DAAs), Boceprevir (BOC) and Telaprevir (TEL) have significantly
improved SVR rates for HCV Genotype 1 (GT1) patients. The objective was to project
potential costs of DAAs on GT1 patients in the VHA.METHODS:A decision-analytic
Markov model was developed to simulate the lifetime progression of HCV disease
and to estimate the costs and clinical impacts of DAA in the current cohort of
103,331 GT1 treatment-naïve patients. Estimated federal pricing for drug costs and
published response-guided antiviral efficacy data were used in the model. Treat-
ment costs included drugs, inpatient/outpatient visits, and laboratory tests. We
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